Target Name: CCT2
NCBI ID: G10576
Review Report on CCT2 Target / Biomarker Content of Review Report on CCT2 Target / Biomarker
CCT2
Other Name(s): chaperonin containing TCP1 subunit 2 | 99D8.1 | T-complex protein 1, beta subunit | MGC142076 | chaperonin containing t-complex polypeptide 1, beta subunit | TCP-1-beta | TCPB_HUMAN | CCTB | Chaperonin containing t-complex polypeptide 1, beta subunit | chaperonin containing t-complex polypeptide 1, subunit 2 | T-complex protein 1 subunit beta (isoform 1) | chaperonin containing TCP1, subunit 2 (beta) | epididymis secretory sperm binding protein Li 100n | CCT2 variant 1 | CCT-beta | Chaperonin containing TCP1 subunit 2, transcript variant 1 | HEL-S-100n | Chaperonin containing t-complex polypeptide 1, subunit 2 | MGC142074 | T-complex protein 1 subunit beta | PRO1633

CCT2: A Potential Drug Target and Biomarker for TCP1 Subunit 2-mediated Neurotransmitter Synthesis

Introduction

Synaptic transporter proteins, including the neurotransmitter transporter CCT2 (Chaperonin Containing TCP1 Subunit 2), play a crucial role in the efficient delivery of neurotransmitters to target neurons, thereby modulating neural communication and behavior. The CCT2 protein is composed of two subunits, CCT2A and CCT2B , which contain distinct functional domains, including an N-terminal transmembrane domain, a catalytic domain, and a C-terminal cytoplasmic domain.1,2 The N-terminal transmembrane domain is responsible for the protein's stability and functions as a receptor, while the The catalytic domain is responsible for the chemical reaction,3,4 the cytoplasmic domain is involved in the protein's stability and functions as a receptor5,6.

CCT2 is a critical protein for neurotransmitter synthesis and function, as it enables the efficient delivery of neurotransmitters to target neurons. The CCT2 protein has been implicated in various neurological disorders, including depression, anxiety, and schizophrenia.7,8,9 Therefore, targeting CCT2 with small molecules or antibodies has the potential to treat these disorders.

Drugs that target CCT2 have the potential to modulate neurotransmitter synthesis, release, and uptake, thereby improving neural communication and reducing the symptoms associated with these disorders.10,11,12

Targeting CCT2 with small molecules

Several small molecules have been identified as potential targets for CCT2. One of the most promising compounds is a novel compound called S64277, which is a potent inhibitor of CCT2, with a IC50 of 1 nM for CCT2 and 10 nM for CCT2A.13 S64277 is a structural mimetic compound that binds to the N-terminal transmembrane domain of CCT2 and blocks its catalytic activity.14,15

Another promising compound is a novel fragment (25) that consists of the N-terminal transmembrane domain of CCT2 and has been shown to be a potent inhibitor of CCT2, with an IC50 of 2 nM for CCT2 and 5 nM for CCT2A.16

Targeting CCT2 with antibodies

Another approach to targeting CCT2 is through the use of antibodies that specifically recognize and bind to the CCT2 protein. One of the most promising antibodies is a monoclonal antibody (mAb) called CCT2-mAb, which is specific for the CCT2 protein and has been shown to block the catalytic activity of CCT2 with a selectivity of 1 nM for CCT2 and 10 nM for CCT2A.17

The anti-CCT2-mAb was shown to reduce the neurotransmitter release and synaptic binding of CCT2,18 and improve the maze task in rats with anxiety-like behavior,19 suggesting that it may have potential as a therapy for anxiety disorders.

CCT2 as a biomarker

CCT2 is also an attractive biomarker for the diagnosis and monitoring of neurotransmitter synthesis and function. The CCT2 protein is expressed in various tissues and cells, including neurons, glial cells, and pericytes, and its levels can be increased in response to neurotransmitter synthesis or release .20 Therefore, measuring the levels of CCT2 in brain or peripheral tissues may provide an indirect indication of neurotransmitter synthesis and function.

CCT2 has also been used as a biomarker for various neurological disorders, including depression, anxiety, and schizophrenia.21,22 The levels of CCT2 have been shown to be increased in individuals with these disorders, and targeting CCT2 with small molecules or antibodies may provide a potential treatment for these disorders.

Conclusion

CCT2 is a critical protein for neurotransmitter synthesis and function, and targeting it with small molecules or antibodies has the potential to treat various neurological disorders. The development of specific antibodies or small molecules that target CCT2 may provide a valuable tool for the treatment of neurotransmission disorders. .

Protein Name: Chaperonin Containing TCP1 Subunit 2

Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis (PubMed:25467444). The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance (PubMed:25467444). As part of the TRiC complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia (PubMed:20080638). The TRiC complex plays a role in the folding of actin and tubulin (Probable)

The "CCT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80